Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer.

Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G.

J Clin Oncol. 2005 Apr 10;23(11):2534-43. Epub 2005 Feb 7.

PMID:
15699478
2.

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.

Attard G, Kitzen J, Blagden SP, Fong PC, Pronk LC, Zhi J, Zugmaier G, Verweij J, de Bono JS, de Jonge M.

Br J Cancer. 2007 Nov 19;97(10):1338-43. Epub 2007 Nov 13.

3.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

Agus DB, Sweeney CJ, Morris MJ, Mendelson DS, McNeel DG, Ahmann FR, Wang J, Derynck MK, Ng K, Lyons B, Allison DE, Kattan MW, Scher HI.

J Clin Oncol. 2007 Feb 20;25(6):675-81.

PMID:
17308272
4.

Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.

Yamamoto N, Yamada Y, Fujiwara Y, Yamada K, Fujisaka Y, Shimizu T, Tamura T.

Jpn J Clin Oncol. 2009 Apr;39(4):260-6. doi: 10.1093/jjco/hyp006. Epub 2009 Mar 4.

5.

A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors.

Albanell J, Montagut C, Jones ET, Pronk L, Mellado B, Beech J, Gascon P, Zugmaier G, Brewster M, Saunders MP, Valle JW.

Clin Cancer Res. 2008 May 1;14(9):2726-31. doi: 10.1158/1078-0432.CCR-07-1980.

6.

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.

Gordon MS, Matei D, Aghajanian C, Matulonis UA, Brewer M, Fleming GF, Hainsworth JD, Garcia AA, Pegram MD, Schilder RJ, Cohn DE, Roman L, Derynck MK, Ng K, Lyons B, Allison DE, Eberhard DA, Pham TQ, Dere RC, Karlan BY.

J Clin Oncol. 2006 Sep 10;24(26):4324-32. Epub 2006 Aug 8. Erratum in: J Clin Oncol. 2008 Jun 1;26(16):2793.

PMID:
16896006
7.

Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.

Herbst RS, Davies AM, Natale RB, Dang TP, Schiller JH, Garland LL, Miller VA, Mendelson D, Van den Abbeele AD, Melenevsky Y, de Vries DJ, Eberhard DA, Lyons B, Lutzker SG, Johnson BE.

Clin Cancer Res. 2007 Oct 15;13(20):6175-81.

8.
9.

Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of Pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer.

Gianni L, Lladó A, Bianchi G, Cortes J, Kellokumpu-Lehtinen PL, Cameron DA, Miles D, Salvagni S, Wardley A, Goeminne JC, Hersberger V, Baselga J.

J Clin Oncol. 2010 Mar 1;28(7):1131-7. doi: 10.1200/JCO.2009.24.1661. Epub 2010 Feb 1.

10.

Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab.

Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, McKeever K, Sliwkowski MX.

Cancer Immunol Immunother. 2006 Jun;55(6):717-27. Epub 2005 Sep 3.

PMID:
16151804
11.

Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.

Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D.

Pharm Res. 2006 Jun;23(6):1275-84. Epub 2006 May 26.

PMID:
16715358
12.

Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Pegram MD, Borges VF, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedli Stark F, Courtenay Luck N.

Breast Cancer Res. 2009;11(5):R73. doi: 10.1186/bcr2409.

13.

HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.

Kristjansdottir K, Dizon D.

Expert Opin Biol Ther. 2010 Feb;10(2):243-50. doi: 10.1517/14712590903514090. Review.

PMID:
20001562
14.

Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer.

Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA.

J Clin Oncol. 2010 Jun 1;28(16):2698-704. doi: 10.1200/JCO.2009.26.2071. Epub 2010 Apr 26.

PMID:
20421541
15.

A phase I, dose-escalation study of TB-403, a monoclonal antibody directed against PlGF, in patients with advanced solid tumours.

Lassen U, Nielsen DL, Sørensen M, Winstedt L, Niskanen T, Stenberg Y, Pakola S, Stassen JM, Glazer S.

Br J Cancer. 2012 Feb 14;106(4):678-84. doi: 10.1038/bjc.2011.609. Epub 2012 Jan 24.

16.

MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study.

Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, Piha-Paul S, Wheler JJ, Fu S, Tsimberidou AM, Stecher M, Mohanty P, Simard J, Kurzrock R.

Lancet Oncol. 2014 May;15(6):656-66. doi: 10.1016/S1470-2045(14)70155-X. Epub 2014 Apr 17.

PMID:
24746841
17.

Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.

Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK.

Clin Ther. 2003 Jun;25(6):1700-21.

PMID:
12860493
18.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, Bagatell R, Ma W, Wheler J, Rosen N, Norton L, Cropp GF, Johnson RG, Hannah AL, Hudis CA.

J Clin Oncol. 2007 Dec 1;25(34):5410-7.

PMID:
18048823
19.

Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.

Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B.

Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14.

PMID:
25119184
20.

Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel.

Leyland-Jones B, Gelmon K, Ayoub JP, Arnold A, Verma S, Dias R, Ghahramani P.

J Clin Oncol. 2003 Nov 1;21(21):3965-71. Epub 2003 Sep 24.

PMID:
14507946

Supplemental Content

Support Center